Jessica Tsai, MD, PhD - Pediatric Hematology and Oncology

Member for

8 months
Submitted by dfci_admin on Wed, 12/22/2021 - 04:00
First Name
Jessica
Middle Name
W.
Last Name
Tsai
Professional Title
MD, PhD
Fellowships
  • Boston Children's Hospital/Dana-Farber Cancer Institute, Pediatric Hematology/Oncology, 2021
Residency
  • Boston Combined Residency Program, Boston Children's Hospital/ Boston Medical Center, Pediatrics, 2018
Medical School
  • Stanford University School of Medicine, 2015
Biography

Jessica Tsai, MD, PhD is an Instructor in Pediatrics at Harvard Medical School, an Attending Physician in Pediatric Hematology/oncology at Dana-Farber Cancer Institute and Boston Children's Hospital, and a post-doctoral research fellow in the Laboratory of Pratiti Bandopadhayay at Dana-Farber. Dr. Tsai studies oncogenic mechanisms underlying pediatric brain tumors, in particular diffuse intrinsic pontine glioma and low grade gliomas. She completed her Bachelor of Science in Biological Sciences with Honors in Neurobiology at Stanford University. She then completed her MD, PhD training in the medical Scientist Training Program at Stanford University School of Medicine. She completed her residency training in the Boston Combined Residency Program, and her pediatric oncology training at Boston Children's Hospital and Dana-Farber Cancer Institute.

Abstract

Jessica Tsai, MD, PhD is part of the pediatric hematology and oncology team at Dana-Farber/Boston Children’s Cancer and Blood Disorders Center.

NPI
1871987396
Provider ID
50685
Provider Type
Provider Status
Active
Accepting New Patients
Yes
Academic Title
Physician
Instructor in Pediatrics, Harvard Medical School
Board Certifications
  • Pediatrics, 2019
Office Phone
617-632-3270
Appointment Phone
617-632-3270
Fax
617-632-4410

David Williams, MD - Pediatric Hematology and Oncology

Member for

8 months
Submitted by dfci_admin on Thu, 10/28/2021 - 17:25
First Name
David
Middle Name
A.
Last Name
Williams
Professional Title
MD
Preferred Contact Method
appointment phone
Fellowships
  • Boston Children's Hospital/Dana-Farber Cancer Institute, Pediatric Hematology/Oncology, 1985
Residency
  • Cincinnati Children's Hospital Medical Center, Pediatrics, 1982
Medical School
  • Indiana University School of Medicine, Medicine, 1979
Internships
  • Pediatrics, Cincinnati's Children's Hospital Medical Center, Cincinnati, OH, 1980
Biography
Dr. David A. Williams is a graduate of Indiana State University and Indiana University School of Medicine. After training in Pediatrics at Cincinnati Children's Hospital Medical Center, Dr. Williams completed fellowship training in Pediatric Hematology/Oncology at Dana-Farber/Boston Children's. He completed his research training here and at the Whitehead Institute at the Massachusetts Institute of Technology. He then became a faculty member at Harvard Medical School and of the Howard Hughes Medical Institute (HHMI).
Remote video URL
Abstract

David Williams, MD is part of the pediatric hematology and oncology team at Dana-Farber/Boston Children’s Cancer and Blood Disorders Center.

NPI
1871658682
Provider ID
29755
Provider Type
Provider Status
Active
Accepting New Patients
Yes
Academic Title
Associate Chairman, Department of Pediatric Oncology
Chief, Hematology/Oncology, Boston Children's Hospital
Institute Physician
Leland Fikes Professor of Pediatrics, Harvard Medical School
Board Certifications
  • Pediatrics
Clinical Interests

Aplastic anemia, Blood formation, Chronic granulomatous disease, Fanconi anemia and other genetic disorders, Gene therapy, Genetic blood disorders, Hematopoiesis, Neutropenia and neutrophil dysfunction syndromes, Stem cell biology, Viral vectors

Office Phone
617-919-2697
Appointment Phone
617-355-8246, ext. 1
Fax
617-730-0934

Jennifer Whangbo, MD, PhD - Pediatric Hematology and Oncology

Member for

8 months
Submitted by dfci_admin on Thu, 10/28/2021 - 17:25
First Name
Jennifer
Middle Name
S.
Last Name
Whangbo
Professional Title
MD, PhD
Preferred Contact Method
appointment phone
Fellowships
  • Boston Children's Hospital/Dana-Farber Cancer Institute, Pediatric Hematology/Oncology
Residency
  • Boston Combined Residency Program, Boston Children's Hospital/Boston Medical Center, Pediatrics
Medical School
  • University of California, Los Angeles
Internships
  • Boston Combined Residency Program
Abstract

Jennifer Whangbo, MD, PhD is part of the pediatric hematology and oncology team at Dana-Farber/Boston Children’s Cancer and Blood Disorders Center.

NPI
1992766984
Provider ID
29775
Provider Type
Provider Status
Active
Accepting New Patients
Yes
Academic Title
Physician
Instructor in Pediatrics, Harvard Medical School
Board Certifications
  • Pediatric Hematology/Oncology
Clinical Interests

Hematopoietic stem cell transplantation

Office Phone
617-632-2664
Appointment Phone
617-632-3961
Fax
617-632-4410
Treatment Centers

Ari Wassner, MD - Pediatric Hematology and Oncology

Member for

8 months
Submitted by dfci_admin on Thu, 10/28/2021 - 17:25
First Name
Ari
Middle Name
J.
Last Name
Wassner
Professional Title
MD
Fellowships
  • Boston Children's Hospital, Pediatric Endocrinology, 2012
Residency
  • Boston Combined Residency Program in Pediatrics, 2008
Medical School
  • Harvard Medical School, 2005
Biography

Dr. Wassner is Medical Director of the Thyroid Center at Boston Children's Hospital and Assistant Professor of Pediatrics at Harvard Medical School in Boston, Massachusetts. He earned his MD from Harvard Medical School, and he completed residency and chief residency in Pediatrics followed by fellowship in Pediatric Endocrinology at Boston Children's Hospital. In addition to practicing general pediatric endocrinology, Dr. Wassner's clinical specialties are in pediatric endocrine tumors and pediatric thyroid disease, and he is actively engaged in clinical research in these areas.

Remote video URL
Abstract

Ari Wassner, MD is part of the pediatric hematology and oncology team at Dana-Farber/Boston Children’s Cancer and Blood Disorders Center.

Provider ID
50531
Provider Type
Provider Status
Active
Accepting New Patients
Yes
Academic Title
Assistant Professor of Pediatrics, Harvard Medical School
Board Certifications
  • Pediatric Endocrinology, 2013
  • Pediatrics, 2008
Clinical Interests

Endocrine oncology, Pediatric endocrine tumors, Pediatric endocrinology, Pheochromocytoma/Paraganglioma

Office Phone
617-355-7476
Appointment Phone
617-632-5508
Treatment Centers

Loren Walensky, MD, PhD - Pediatric Hematology and Oncology

Member for

8 months
Submitted by dfci_admin on Thu, 10/28/2021 - 17:25
First Name
Loren
Middle Name
D.
Last Name
Walensky
Professional Title
MD, PhD
Email ID
loren_walensky@dfci.harvard.edu
Preferred Contact Method
email
Fellowships
  • Boston Children's Hospital/Dana-Farber Cancer Institute, Pediatric Hematology/Oncology
Residency
  • Boston Combined Residency Program, Boston Children's Hospital/Boston Medical Center, Pediatrics
Medical School
  • Johns Hopkins University School of Medicine
Biography
Dr. Walensky received his MD and PhD degrees from Johns Hopkins University School of Medicine in 1997. He trained at the Boston Combined Residency Program in pediatrics, completed a fellowship in pediatric hematology-oncology at Dana-Farber and Boston Children's Hospital, and is board-certified in pediatric hematology/oncology. Dr. Walensky joined Dana-Farber as an attending physician in pediatric hematology/oncology in 2003 and founded his cancer chemical biology research laboratory in 2006. His research involves the development of highly specific and stable "stapled peptides" that preserve the structure of biologically-active peptide helices, maximizing their potential as novel tools to elucidate oncogenic pathways and as prototype therapies for cancer. A stapled peptide drug based on his research is currently undergoing clinical testing in a diversity of human cancers. Dr. Walensky is currently Principal Investigator and Attending Physician in the Department of Pediatric Oncology at the Dana-Farber/Boston Children's Cancer and Blood Disorders Center; Professor Pediatrics at Harvard Medical School; and Director of the Harvard/MIT MD-PhD Program.
Remote video URL
Abstract

Loren Walensky, MD, PhD is part of the pediatric hematology and oncology team at Dana-Farber/Boston Children’s Cancer and Blood Disorders Center.

NPI
1508896853
Provider ID
29677
Provider Type
Provider Status
Active
Accepting New Patients
Yes
Academic Title
Physician
Principal Investigator, Linde Program in Cancer Chemical Biology
Professor of Pediatrics, Harvard Medical School
Award or Recognition
  • Burroughs Wellcome Career Award in Biomedical Science 2005
  • V Foundation Scholar Award 2004
  • American Society of Hematology Scholar Award 2003
  • "Alex's Team" Foundation Oncology Research Award 2003
Board Certifications
  • Pediatric Hematology/Oncology, 2003
  • Pediatrics, 2002
Clinical Interests

Hematologic malignancies

Physician Website
Research

Chemical Biology of Deregulated Apoptotic and Transcriptional Pathways

Extensive research into the origin of cancer has led to the identification of genetic and molecular mistakes that trigger the overproduction or hyperactivity of specific cancer-causing proteins. The structural complexity and intracellular localization of these protein targets can hamper the development of anticancer drugs. The small subunits of proteins, called peptides, are essential components of the interaction surfaces between proteins, and are nature's keys to cancer's lock on cellular survival. Thus, the chemical production of peptides is another strategy for subverting cancer proteins, since natural peptides display evolutionarily-honed binding specificity for their targets. However, the ability to use small peptides made in the laboratory to block cancer has been hindered by their loss of natural architecture, vulnerability to degradation, and difficulty entering cells to exert their anticancer effects.Our work focuses on developing and applying new approaches to chemically brace or "staple" natural peptides so that their shape, and therefore their anticancer activity, can be restored. Optimizing natural peptides in this way may provide alternate compounds to study protein interactions and manipulate biological pathways within cells to treat human disease. To that end, we have used a chemical strategy, termed "hydrocarbon-stapling," to make a panel of anticancer peptides with markedly improved pharmacological properties. We have demonstrated that the stapled peptides retain their natural shape, are resistant to degradation, and can enter and kill leukemia cells by neutralizing their cancer-causing proteins. When administered to mice with leukemia, a stapled peptide successfully blocked cancer growth and prolonged the lives of treated animals. Our ongoing work employs this new peptide-stapling strategy to produce diverse panels of anticancer peptides, in order to study and deactivate aberrant apoptotic and transcriptional pathways in a variety of human tumors. Thus, our goal is to produce an arsenal of new compounds - a "chemical toolbox" - to investigate and block protein interactions that can cause cancer. To achieve this goal, we use structural biology analyses, synthetic chemistry techniques, and biochemical, cellular, and mouse-model experiments to systematically explore the biological effects of the novel peptidic compounds we generate.

Office Phone
617-632-6307
Appointment Phone
888-733-4662 (new)
617-632-3270 (established)
Fax
617-582-8240

Lynda Vrooman, MD - Pediatric Hematology and Oncology

Member for

8 months
Submitted by dfci_admin on Thu, 10/28/2021 - 17:25
First Name
Lynda
Middle Name
M.
Last Name
Vrooman
Professional Title
MD
Preferred Contact Method
appointment phone
Fellowships
  • Boston Children's Hospital/Dana-Farber Cancer Institute, Pediatric Hematology/Oncology
Residency
  • Boston Combined Residency Program, Boston Children's Hospital/Boston Medical Center, Pediatrics
Medical School
  • Harvard Medical School
Internships
  • Boston Combined Residency Program
Abstract

Lynda Vrooman, MD is part of the pediatric hematology and oncology team at Dana-Farber/Boston Children’s Cancer and Blood Disorders Center.

NPI
1962679548
Provider ID
29774
Provider Type
Provider Status
Active
Accepting New Patients
Yes
Academic Title
Associate Medical Director, David B. Perini, Jr. Quality of Life Clinic
Senior Physician
Assistant Professor of Pediatrics, Harvard Medical School
Board Certifications
  • Pediatric Hematology/Oncology
  • Pediatrics
Clinical Interests

Acute lymphoblastic leukemia (ALL), Survivorship

Office Phone
617-632-2659
Appointment Phone
888-733-4662 (new)
617-632-3270 (established)
Fax
617-632-2473

Richard Voit, MD, PhD - Pediatric Hematology and Oncology

Member for

8 months
Submitted by dfci_admin on Thu, 10/28/2021 - 17:25
First Name
Richard
Middle Name
A.
Last Name
Voit
Professional Title
MD, PhD
Fellowships
  • Dana-Farber Cancer Institute and Boston Children's Hospital, 2020
Residency
  • Boston Children's Hospital, 2017
Medical School
  • University of Texas Southwestern Medical Center, 2014
Biography
Dr. Voit is a physician-scientist interested in transcriptional factors that control hematopoietic stem cell maintenance and differentiation. He is also a practicing pediatric hematologist and oncologist.
Abstract

Richard Voit, MD, PhD is part of the pediatric hematology and oncology team at Dana-Farber/Boston Children’s Cancer and Blood Disorders Center.

Provider ID
50601
Provider Type
Provider Status
Active
Accepting New Patients
Yes
Academic Title
Physician
Instructor in Pediatrics, Harvard Medical School
Clinical Interests

Gene therapy

Office Phone
617-919-6645
Appointment Phone
617-355-8246
Fax
617-730-0641

Karen Tang, MD - Pediatric Hematology and Oncology

Member for

8 months
Submitted by dfci_admin on Thu, 10/28/2021 - 17:25
First Name
Karen
Last Name
Tang
Professional Title
MD
Fellowships
  • New York University
Residency
  • University of Connecticut
Medical School
  • SUNY Upstate Medical University
Biography
Dr. Karen Tang is an Instructor in Pediatrics at Harvard Medical School and an Attending Physician in Pediatric Hematology and Oncology at Dana-Farber Cancer Institute and Boston Children's Hospital. She is a hospitalist dedicated to providing exceptional care for hospitalized pediatric hematology and oncology patients. She has previously worked as a pediatric hospitalist and clinical instructor at Memorial Sloan Kettering Cancer Center. She completed her residency in pediatrics at University of Connecticut and her fellowship in pediatric hematology and oncology at New York University. She completed her medical degree at SUNY Upstate Medical University. She also completed a master's degree in clinical and translational investigation at New York University and master's degree in biotechnology at Columbia University.
Abstract

Karen Tang, MD is part of the pediatric hematology and oncology team at Dana-Farber/Boston Children’s Cancer and Blood Disorders Center.

Provider ID
50609
Provider Type
Provider Status
Active
Accepting New Patients
Yes
Academic Title
Physician
Instructor in Pediatrics, Harvard Medical School
Clinical Interests

Long-term follow-up care, Pediatric brain tumors

Office Phone
617-355-8066

Joelle Straehla, MD - Pediatric Hematology and Oncology

Member for

8 months
Submitted by dfci_admin on Thu, 10/28/2021 - 17:25
First Name
Joelle
Last Name
Straehla
Professional Title
MD
Fellowships
  • Dana-Farber/Boston Children's Cancer and Blood Disorders Center, Pediatric Hematology/Oncology, 2019
Residency
  • University of Washington/Seattle Children's Hospital, 2016
Medical School
  • Northwestern University Feinberg School of Medicine, 2013
Biography
Dr. Straehla studies novel drug delivery strategies for the treatment of pediatric brain tumors. Her research aims to improve the delivery of therapeutic agents across the blood-brain barrier and into tumors while minimizing damage to the developing brain.
Remote video URL
Abstract

Joelle Straehla, MD is part of the pediatric hematology and oncology team at Dana-Farber/Boston Children’s Cancer and Blood Disorders Center.

Provider ID
50546
Provider Type
Provider Status
Active
Accepting New Patients
Yes
Academic Title
Physician
Instructor in Pediatrics, Harvard Medical School
Award or Recognition
  • Helen Fellow, Dana-Farber Cancer Institute's Helen Gurley Brown (HGB) Presidential Initiative (2020-2022)
Board Certifications
  • Pediatrics, 2016
Clinical Interests

Drug delivery strategies, Novel therapeutics

Office Phone
617-632-3270
Appointment Phone
617-632-3270
Fax
617-632-4410
Treatment Centers

Kimberly Stegmaier, MD - Pediatric Hematology and Oncology

Member for

8 months
Submitted by dfci_admin on Thu, 10/28/2021 - 17:25
First Name
Kimberly
Last Name
Stegmaier
Professional Title
MD
Email ID
kimberly_stegmaier@dfci.harvard.edu
Preferred Contact Method
email
Fellowships
  • Boston Children's Hospital/Dana-Farber Cancer Institute, Pediatric Hematology/Oncology
Residency
  • Boston Combined Residency Program, Boston Children's Hospital/Boston Medical Center, Pediatrics
Medical School
  • Harvard Medical School, 1996
Biography

Kimberly Stegmaier, M.D., is a Professor of Pediatrics at Harvard Medical School, a Principal Investigator in Pediatric Oncology at the Dana-Farber Cancer Institute (DFCI), and an Attending Physician at the Boston Children’s Hospital Boston (BCH) and DFCI. She is the Co-director of the Pediatric Hematologic Malignancies Program at DFCI and BCH and is also an Associate Member of the Broad Institute of Harvard and MIT. She received her B.S. from Duke University and her M.D. from Harvard Medical School. She completed her residency at BCH and a post-doctoral pediatric hematology-oncology fellowship at DFCI/BCH. In 2006, she launched her own laboratory effort at DFCI.

Dr. Stegmaier’s laboratory integrates chemical biology, genomic, and proteomic approaches to discover new lead compounds and protein targets for cancer therapy. She has focused her efforts on the acute leukemias and two pediatric solid tumors of childhood: Ewing sarcoma and neuroblastoma.

Abstract

Kimberly Stegmaier, MD is part of the pediatric hematology and oncology team at Dana-Farber/Boston Children’s Cancer and Blood Disorders Center.

NPI
1801864202
Provider ID
29676
Provider Type
Provider Status
Active
Accepting New Patients
Yes
Academic Title
Co-Director of the Hematologic Malignancy Center (Basic and Translational Research)
Physician
Ted Williams Chair
Professor of Pediatrics, Harvard Medical School
Award or Recognition
  • Joanne Levy, MD, Memorial Award for Outstanding Achievement, American Society of Hematology, 2006
  • Genome Technology "Tomorrow's Principal Investigator" Award, 2007
  • American Society for Clinical Investigation, Elected Member, 2009

  • SU2C Innovative Research Grant Recipient, 2009

  • Society for Pediatric Research (SPR) Young Investigator Award, 2012

  • Stephen E. Sallan Leadership Award, 2012

  • Osler Young Investigator Award, Interurban Clinical Club, 2013

  • Clifford Barger Excellence in Mentoring Award, Harvard Medical School, 2014

  • Helen Mentor, Dana-Farber Cancer Institute's Helen Gurley Brown (HGB) Presidential Initiative, 2020-2022
Board Certifications
  • Pediatric Hematology/Oncology, 2002
Clinical Interests

Cancer genomics, Chemical screening, Ewing sarcoma, Hematologic malignancies, Neuroblastoma

Research

Principal Investigator

My research program focuses on the integration of “omic” approaches for the identification of new protein targets and small-molecule modulators of malignancy with an eye toward clinical translation. Cancer discovery efforts in my laboratory have focused on the alteration of the malignant state (e.g., AML and neuroblastoma differentiation) and the modulation of pharmacologically challenging oncoproteins (e.g., EWS/FLI in Ewing sarcoma, MYCN in neuroblastoma, and NOTCH1 in T-ALL.) Most recently, we are applying an integrated approach to discover new therapeutic opportunities in these malignancies with deep genomic characterization of primary tumors, kinase activity profiling for immediately druggable targets, functional genomic screening for new tumor dependencies and chemical screening for modulators of relevant oncogenic drivers. Clinical trials for patients with AML and Ewing sarcoma have resulted from our research and a trial testing BET bromodomain inhibitors in patients with MYCN amplified neuroblastoma is in development.

 

Office Phone
617-632-4438
Appointment Phone
888-733-4662 (new)
617-632-3270 (established)
Fax
617-632-4850
Subscribe to Pediatric Hematology/Oncology